-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of the National Medical Insurance Bureau published a large number of replies to the proposals and suggestions of deputies to the National People's Congress and members of the National Committee of the Chinese People's Political Consultative Conference, in which drugs and devices will enter the centralized procurement or will not be included in the centralized procurement for the time being
.
01 It is clear that the three types of drugs will not be included in the centralized procurement for the time being Innovative medical devices are still difficult to collect
01 It is clear that the three types of drugs will not be included in the centralized procurement for the time being Innovative medical devices are still difficult to collect The National Health Insurance Administration lists three types of drugs that are temporarily not included in the scope of centralized procurement, namely innovative drugs, drugs containing ingredients from endangered wild animals, orphan drugs and shortage drugs
.
For the reasons why the three types of drugs are temporarily not included in the centralized procurement, the National Medical Insurance Bureau has explained them one by one, such as:
Collective procurement has become regular, and its scope is further expanding, from early drugs to medical device categories
.
For the field of medical devices, the National Medical Insurance Administration proposed that it is still difficult to implement the quantitative method
of innovative medical devices.
.
In September this year, the National Health Insurance Administration mentioned in the "Reply to Recommendation No.
4955 of the Fifth Session of the 13th National People's Congress" that it is still difficult to implement the dosage method
because the clinical use of innovative medical devices is not yet mature and the amount of use is temporarily difficult to estimate.
In the process of centralized volume procurement, the National Medical Insurance Bureau will reasonably determine the proportion of volume according to factors such as clinical use characteristics, market competition pattern and the number of selected enterprises, and leave a certain market outside of centralized volume procurement to provide space
for innovative products to open up the market.
.
In October, the National Medical Insurance Administration pointed out that 3D printing innovative products are still in the initial stage, the market competition is not sufficient, and the product characteristics are more complex, some products have the characteristics of personalized customization, and their cost and efficacy are difficult to compare
with mass production products.
Therefore, in the collection and collection of spine consumables, 3D printing spine products are not clearly required to participate, but the enterprise independently chooses whether to participate in the collection
.
.
Zhong Chongming, an expert in health service operation, told Cyberblue that the relatively stable and predictable centralized procurement policy (collection or temporary non-procurement) is conducive to the development of
domestic innovative enterprises.
Innovative medical devices have a very direct and important impact on the construction of hospital departments, and the centralized procurement of medical device products is different from that of pharmaceutical consumables, and the connotation, professionalism and effect impact are more complex
.
On September 6, the National Health Insurance Bureau proposed in the "Letter on the Reply to the Proposal No.
01535 (Social Management No.
133) of the Fifth Meeting of the 13th National Committee of the Chinese People's Political Consultative Conference" to further improve the centralized procurement rules
.
At the same time, the National Medical Insurance Bureau also made it clear that it is building a unified national centralized pharmaceutical procurement market
.
It is foreseeable that although the National Medical Insurance Bureau pointed out that drugs and equipment consumables that may not be included in collective procurement for the time being, the pace of collective procurement is still advancing
.
02 Biological drugs or re-collection Tumor genetic testing will be included in centralized procurement
02 Biological drugs or re-collection Tumor genetic testing will be included in centralized procurement The scope of the "no restricted zone" for collective procurement has been expanding, and recently, the National Medical Insurance Administration has also given a number of replies
to which drugs may enter the centralized procurement.
For example, in the field of pharmaceuticals, the National Medical Insurance Administration will, on the basis of the existing successful experience in centralized procurement, combine the characteristics of biological drugs, and continuously improve the rules for the centralized procurement of
biological drugs.
The National Medical Insurance Bureau mentioned in its reply that compared with chemical drugs, biological drugs have no consistency evaluation as support, the naming is complex and diverse, and the capacity climbing and improvement are slower, so the National Medical Insurance Bureau and relevant departments have further adjusted and improved
the rules on the basis of the centralized procurement of chemical drugs.
the rules on the basis of the centralized procurement of chemical drugs.
The national centralized procurement has carried out 7 batches, including 6 batches of chemical drugs and 1 batch of biological drugs (special insulin).
The sixth batch of national procurement in the form of special projects included a total of 81 products, impacting the 10 billion insulin market
.
In addition to national centralized procurement, local centralized procurement has also begun to enter the field of
biological drugs.
This time, the National Medical Insurance Bureau has clearly taken the next step in the rules for the centralized procurement of biological drugs, and the centralized procurement of biological drugs may continue
.
At present, there are many pharmaceutical companies in China that have laid out biosimilars, such as Henlius' rituximab and trastuzumab
.
Recently, the Yunnan Provincial Government Procurement and Transfer Center announced the notice of online trading of biological products (biosimilars) drugs in Yunnan Province in 2022, and the newly approved biological drugs will be officially launched on the drug trading system of the centralized drug procurement platform of Yunnan Province from October 17, 2022, involving 167 biological products, including adalimumab, bevacizumab, etc.
(specific list attached at the end of the article).
The call for the collection of biological drugs is getting louder and louder
.
However, at present, there is still a lot of difficulty
in the collection of biological drugs.
For example, how to expand biopharmaceutical production capacity, how to change the supply in the short term, etc
.
In the later stage, once the biopharmaceutical is collected again, these are urgent problems
that need to be solved.
In the field of medical devices, the National Medical Insurance Administration said that tumor genetic testing is a medical service project, and according to the current policy, the basic medical services provided by public medical institutions are subject to government guidance prices
.
At present, it is guiding local governments to explore centralized procurement of diagnostic reagents in accordance with the principle of "separation of technology and consumption", promote the return of reagent prices to reasonable and fair, and drive the price of related medical service items to decline
.
Zhong Chongming said that tumor genetic testing is in vitro diagnosis, centralized procurement can reduce the price and volume, and the medical insurance department may have seen the effectiveness of
this application technology.
He believes that tumor genetic testing and consumables should be the key work
of the next stage of collective procurement to "overcome difficulties".
"The centralized procurement of tumor genetic testing products is expected to be very similar to the centralized procurement of dental implants, that is, medical insurance will not include specific products in the scope of medical insurance payment for the time being, and private hospitals will not be completely forced to participate, providing users with some opportunities for
affordable choices.
"
03 The scope of drug centralized procurement, medical consumables, and centralized procurement institutions should be expanded
03 The scope of drug centralized procurement, medical consumables, and centralized procurement institutions should be expanded Cyberblue combed through multiple responses from the National Medical Insurance Administration and found that dental implant collection is still the focus of
its continuous promotion.
At the same time, collective procurement and public hospital reform are coordinated development
.
In the field of dental implants, the National Health Insurance Administration pointed out that it will explore the solution of
comprehensive treatment.
It is worth mentioning that at present, many places have announced the list of medical institutions participating in dental implant collection (specific list attached at the end of the article).
According to the previous arrangement of dental implant collection, the next step (December 2022-March 2023) is the implementation stage of the special treatment of special medical service charges and consumables prices for oral implants, and there will be a "review"
in the second half of 2023.
In its reply to Recommendation No.
4831 of the Fifth Session of the 13th National People's Congress, the National Health Insurance Administration mentioned that the scope of centralized procurement of drugs, medical consumables and centralized procurement institutions still needs to be
expanded.
For example, with regard to the scope of medical institutions participating in collective procurement, it is clearly stipulated that all public medical institutions should participate in the collective procurement of drugs, and medical institutions and designated pharmacies designated by medical insurance shall refer to the
requirements of fixed-point agreement management.
expanded.
At the same time, the National Medical Insurance Administration made it clear in its reply to Recommendation No.
8815 of the Fifth Session of the 13th National People's Congress that in the next step, it will continue to guide all localities to improve the centralized procurement of proprietary Chinese medicines and expand the scope of
varieties in an orderly manner.
varieties in an orderly manner.
In other words, the collective procurement of proprietary Chinese medicines will continue, and the range of varieties will be expanded, and the scope of medical institutions' participation in collective procurement will also be expanded
.
The National Medical Insurance Administration also pointed out that it will promote the coordinated development of collective procurement and public hospital reform, and carry out collective procurement
guided by clinical needs.
Medical institutions will independently report the amount
based on the usage of the previous year, taking into account factors such as clinical use and medical technology progress.
For biological drugs and high-value medical consumables that are not supported by consistency evaluation, medical institutions will submit the demand according to the brand, and multiple selections will be implemented at the same time, maintaining a high selection rate and fully respecting clinical choices
.
The relationship between collective procurement and the reform and development of public hospitals will become more and more intense, which also reminds all pharmaceutical companies that it is necessary to
actively participate in collective procurement.
Attached: In 2022, 167 drugs will be traded online for biological products (biosimilars) in Yunnan Province
Attached: In 2022, 167 drugs will be traded online for biological products (biosimilars) in Yunnan Province
List of medical institutions in Hebei Province participating in the centralized procurement of oral implants
List of medical institutions in Hebei Province participating in the centralized procurement of oral implants
